05.11.11
Michael E. Lytton has been appointed Patheon’s executive vice president of Corporate Development and Strategy and general counsel. Mr. Lytton most recently served as executive vice president, Corporate and Business Development at Biogen Idec, where he reported to Jim Mullen, previously chief executive officer of Biogen Idec and now Patheon’s chief executive officer.
Mr. Lytton has 28 years of experience in the pharmaceutical and biotech industry. Most recently, he led Biogen’s corporate development team that executed its corporate partnership strategy, including the in-licensing of several late-stage molecules. Prior to joining Biogen, Mr. Lytton was a general partner with Oxford Bioscience Partners, a venture capital firm investing in therapeutic, diagnostic, and life science tool companies. Prior to Oxford, Mr. Lytton practiced law for 17 years and specialized in representing biomedical companies. Mr. Lytton is currently chairman of the board of Santhera Pharmaceuticals AG.
Mr. Mullen said, “I am so pleased that Michael has agreed to join us. He is an accomplished leader, strategist and negotiator who will bring a deep and broad understanding of the industry and proven skills to help Patheon reach its full potential. I expect that Michael will assist us in building strategic alliances with our pharmaceutical and biotechnology customers as well as emerging companies and their investors, and that he will enable us to add a range of proprietary capabilities and technologies to better serve our customers.”
Mr. Lytton has 28 years of experience in the pharmaceutical and biotech industry. Most recently, he led Biogen’s corporate development team that executed its corporate partnership strategy, including the in-licensing of several late-stage molecules. Prior to joining Biogen, Mr. Lytton was a general partner with Oxford Bioscience Partners, a venture capital firm investing in therapeutic, diagnostic, and life science tool companies. Prior to Oxford, Mr. Lytton practiced law for 17 years and specialized in representing biomedical companies. Mr. Lytton is currently chairman of the board of Santhera Pharmaceuticals AG.
Mr. Mullen said, “I am so pleased that Michael has agreed to join us. He is an accomplished leader, strategist and negotiator who will bring a deep and broad understanding of the industry and proven skills to help Patheon reach its full potential. I expect that Michael will assist us in building strategic alliances with our pharmaceutical and biotechnology customers as well as emerging companies and their investors, and that he will enable us to add a range of proprietary capabilities and technologies to better serve our customers.”